BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022.

Maravai LifeSciences Holdings, Inc. announced the release of its second Environmental, Social and Governance report, which is now available on the Company’s new ESG webpage: https://investors.maravai.com/esg.

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today reported operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces its 2022 annual results and major company business updates.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has entered into an agreement (“the Agreement”) with Roche Diabetes Care Japan Co., Ltd. (Country Manager: Noriko Hattori, “Roche Diabetes Care Japan”) for the development and commercialization of Roche Diabetes Care’s world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.

Shanghai Junshi Biosciences Co., Ltd and Rxilient Biotech announced the collaboration on the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.

Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights.

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses.